Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 363

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 363
---
 were recognized as expense:

                                                                 Year ended December 31,                                                       
  (in thousands of euro)                                                            2022                 2023                 2024             
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Personnel expenses and other short-term employee benefits                                   2,176                2,856                3,835  
  Extra pension benefits                                                              43                   33                 166              
  Share-based compensation                                                                    1,989                2,081                2,302  
  Advisory fees                                                                      661                  471                 —                
  Executive Committee members compensation                                                    4,869                5,441                6,303  

As of December 31, 2024, four two

Hervé Brailly, Chairman of the Supervisory Board in 2023, was Chairman of the Executive Board from 1 January 2024 until he was replaced by Jonathan Dickinson on 1 November 2024.

Calculation of share-based compensation is detailed in Note 11. b.

F-85

Members of the Supervisory Board

The Company recognized a provision of € 310jetons de presence) relating to the year ended December 31, 2024 which should be paid in 2025. This amount includes the compensation for the Chairman of the Supervisory Board. The company recognized a provision of € 348 353

Related parties

Novo Nordisk A/S is a shareholder and has entered into three

At 31 December 2024, 2023 and 2022, respectively, the Company had no

AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab, IPH5201). The payments between the two companies as well as the liabilities and receivables as of 31 December 2024 are as follows:

                                                                  As of December 31, 2024                                     
  (in thousands of euros)                                         Payments                                Assets/Liabilities  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Collection (AstraZeneca towards the Company) / Receivables                                   2,637                     721  
  Payments (the Company towards AstraZeneca) / Liabilities        ( 8,687)                                          ( 1,932)  
  Total                                                           ( 6